Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications ... diabetes drug Mounjaro and weight loss drug ...

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price ...

FILE - President Joe Biden speaks about prescription drug costs at the National Institutes of Health in Bethesda, Md., Dec. 14, 2023. (AP Photo/Andrew Harnik, File) ...

Although Lilly’s Zepbound outperformed Novo Nordisk’s Wegovy (20.2% compared with 13.7%, respectively) in a weight-loss head-to-head study last year, UBS analysts believe that the semaglutide ...

Your guide to what the 2024 US election means for Washington and the world Prices for Novo Nordisk’s blockbuster diabetes and weight-loss drugs Ozempic and Wegovy could face steep price cuts in ...